MONEY

Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 16:00
Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024
Read More

Tags:

Previous Article

Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-P...

Next Article

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Mizuho maintains Outperform rating on Harmony Biosciences

Mizuho maintains Outperform rating on Harmony Biosciences

Tomas Kauer - Mode... Oct 1, 2024

Results of Annual General Meeting of Shareholders

Results of Annual General Meeting of Shareholders

Tomas Kauer - Mode... Sep 18, 2024

Mizuho maintains Outperform rating on Gilead stock with no price target change

Mizuho maintains Outperform rating on Gilead stock with...

Tomas Kauer - Mode... Sep 13, 2024